Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
A Phase 2 Trial of 4 Weeks of ACH-126,443 in Comparison With Continued Lamivudine in Stable Triple Antiretroviral Combination Therapy in HIV-Infected Subjects With Modestly Detectable Viral Load
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85006
- Body Positive, Inc.
-
-
California
-
L.a., California, Forenede Stater
-
San Francisco, California, Forenede Stater, 94115
- Pacific Horizon Medical Group, Inc.
-
-
Florida
-
Ft. Lauderdale, Florida, Forenede Stater, 33306
- Community Health Care Center One, Inc.
-
Miami Beach, Florida, Forenede Stater, 33160
- South Shore Hospital
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30308
- AIDS Research Consortium
-
-
Illinois
-
Chicago, Illinois, Forenede Stater
-
-
New York
-
New York, New York, Forenede Stater, 10019
- St. Lukes Roosevelt Hospital
-
Stony Brook, New York, Forenede Stater, 11794-8153
- Stony Brook University Infectious Disease, Dept. of Medicine
-
-
Texas
-
Houston, Texas, Forenede Stater
-
Houston, Texas, Forenede Stater, 77098
-
-
Virginia
-
Hampton, Virginia, Forenede Stater, 23666
- Hampton Road Medical Specialists
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98122
- Swedish Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Adults ≥18 years of age
- Receiving a stable triple combination antiretroviral regimen including 3TC, one other NRTI and either an NNRTI or a protease inhibitor for at least 4 months (16 weeks)
- Demonstration of initial viral suppression and subsequent rebound to be defined as an initial virological drop of at least 0.5 Logs on a 3TC-containing regimen
- Plasma HIV RNA level > 1000 and < 30,000 copies/mL on two occasions
- Genotypically documented M184V variant of HIV RT
- Clinically stable HIV status with no AIDS-defining events
- CD4 > 200 cells/mm3
- Basic hematologic and chemistry parameters within acceptable limits (defined in protocol)
- All women of child bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity of 25 IU/L of b-HCG) within 72 hours prior to the start of study medication
- No active opportunistic infection requiring treatment
- Subject must be able to provide written informed consent
- Baseline laboratory values measured within 28 days of initiating study drug as follows:
- HGB≥9.0g/dl or HCT≥27% (in the absence of blood transfusions or erythropoietin treatment in the preceding two weeks
- Absolute neutrophil count≥1000 cells/mm(^3) (in the absence of on-going G-CSF therapy
- Platelet count ≥75,000/mm(^3)
- AST <7.0 times the upper limit of normal
- ALT ,7.0 times the upper limit of normal
- Serum creatinine <1.1 times the upper limit of normal
Exclusion Criteria
- Evidence of active HBV infection as demonstrated by HBsAg positivity
- Hepatitis C co-infection
- Concurrent systemic antiviral treatment
- Previous therapy with agents with significant systemic myelosuppressive or cytotoxic potential within 3 months of study start or the expected need for such therapy at study start.
- Alcohol abuse
- Pregnancy or breast-feeding
- Inability to tolerate oral medication
- AST > 7.0 times the upper limit of normal
- ALT > 7.0 times the upper limit of normal
- Any clinical condition or prior therapy that, in the Investigators opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements.
- Use of any other drug or substance with anti-HBV activity
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- RNA-virusinfektioner
- Virussygdomme
- Blodbårne infektioner
- Overførbare sygdomme
- Seksuelt overførte sygdomme, virale
- Seksuelt overførte sygdomme
- Lentivirus infektioner
- Retroviridae infektioner
- Immunologiske mangelsyndromer
- Sygdomme i immunsystemet
- Langsomme virussygdomme
- HIV-infektioner
- Infektioner
- Erhvervet immundefektsyndrom
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Anti-HIV-midler
- Anti-retrovirale midler
- Deexelvucitabin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- ACH443-006
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .